In an 85‑year‑old female on chronic hemodialysis who has completed a 5‑day course of ceftazidime‑avibactam, should ciprofloxacin be given despite a resistant susceptibility test, and what dose would be appropriate if the organism were susceptible?

No, you should NOT give ciprofloxacin if the organism is resistant on susceptibility testing

Administering an antibiotic to which the organism has documented resistance will result in treatment failure, regardless of dose adjustments. The fundamental principle of antimicrobial stewardship and guideline-based care is that therapy must be tailored to susceptibility results once available 1.

---

Why Resistance Matters More Than Dosing

The IDSA/ESMID guidelines explicitly state: "initial empirical therapy should be tailored appropriately on the basis of the infecting uropathogen" 1. When you have susceptibility data showing ciprofloxacin resistance, this is no longer empirical therapy—you have definitive microbiologic evidence that ciprofloxacin will not work.

• Even in studies where patients were randomized to receive drugs to which their organisms were resistant, those patients had significantly worse outcomes unless they experienced clinical failure and were switched 1
• The guidelines consistently emphasize that susceptibility results should guide definitive therapy 2, 1

---

Appropriate Dosing IF the Organism Were Susceptible

For academic completeness, if the organism were susceptible, the ciprofloxacin dosing in an 85-year-old on hemodialysis would be:

Hemodialysis Dosing:

• 250-500 mg every 24 hours after dialysis 3
• Ciprofloxacin is substantially excreted by the kidney, requiring dose reduction in renal impairment 3
• For hemodialysis patients specifically, dosing should occur after the dialysis session since the drug is dialyzable
• The FDA label notes that elderly patients require careful dose selection due to reduced renal function 3

Standard Dosing Context (for susceptible organisms):

• For complicated UTI/pyelonephritis in normal renal function: 500 mg PO twice daily for 7 days 1
• For severe infections requiring IV: 400 mg IV every 8-12 hours 2

---

What You Should Do Instead

Select an alternative antibiotic based on the susceptibility profile. The 2024 EAU guidelines provide a comprehensive list of options for complicated UTIs and multidrug-resistant organisms 2:

Alternative Agents for Resistant Organisms:

• Carbapenems (meropenem 1g TID, imipenem 0.5g TID)
• Ceftazidime-avibactam 2.5g TID (which the patient just completed)
• Ceftolozane-tazobactam 1.5g TID
• Cefiderocol 2g TID
• Aminoglycosides (amikacin 15 mg/kg daily, gentamicin 5 mg/kg daily) with appropriate monitoring
• Trimethoprim-sulfamethoxazole if susceptible

Hemodialysis Considerations:

All of these agents require dose adjustment for hemodialysis. For example:

• Ceftazidime-avibactam in hemodialysis: dosing varies but typically 1.25g after each dialysis session (every 48 hours for thrice-weekly dialysis) 4, 5, 6
• The specific regimen depends on the dialysis schedule and should involve therapeutic drug monitoring when available

---

Critical Pitfalls to Avoid

1. Never treat resistant organisms with the resistant antibiotic hoping "higher doses will work"—this leads to treatment failure and potential mortality in an 85-year-old patient
2. Elderly patients on hemodialysis are at extremely high risk for fluoroquinolone-associated tendon rupture 3—another reason to avoid ciprofloxacin in this population when alternatives exist
3. CNS toxicity from beta-lactams (including ceftazidime-avibactam) can occur with excessive drug accumulation in elderly dialysis patients 7—ensure proper dose adjustments for any chosen agent
4. Resistance patterns matter: The fact that the organism is already resistant to ciprofloxacin after ceftazidime-avibactam failure suggests a highly resistant pathogen requiring careful antibiotic selection 8

---

Clinical Algorithm

1. Review complete susceptibility panel from the culture
2. Identify all susceptible agents with activity against the organism
3. Select the narrowest-spectrum effective agent from the susceptible options
4. Adjust dose for hemodialysis using renal dosing guidelines
5. Time administration after dialysis sessions for dialyzable drugs
6. Monitor clinical response at 48-72 hours
7. Consider infectious disease consultation given multidrug resistance and complex host factors (age 85, hemodialysis, prior broad-spectrum therapy)